Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.
about
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines.Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and BeyondOn the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
P2860
Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@ast
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@en
type
label
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@ast
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@en
prefLabel
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@ast
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@en
P2093
P2860
P356
P1476
Clinical Benefit from Ipilimum ...... iated with Serum CTLA4 Levels.
@en
P2093
Agnes Fermin Lee
Anna M Leung
Delphine J Lee
Donald L Morton
Junko Ozao-Choy
Mark B Faries
Myung Shin-Sim
Omid Hamid
Peter A Sieling
Romela Irene Ramos
P2860
P356
10.3389/FONC.2014.00110
P577
2014-05-16T00:00:00Z